LAEKNA-B-B: Topline data released for the combination of AFURESERTIB and paclitaxel in the treatment of platinum-resistant ovarian cancer (PROC) (PROFECTA-II).
I'm PortAI, I can summarize articles.
LAEKNA-B has released top-line data on the combination of afuresertib and paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC). According to the results of the clinical trial, the combination of afuresertib and paclitaxel demonstrated a significant improvement in progression-free survival in the biomarker-positive subgroup. The safety and tolerability of the combination therapy were manageable. The group plans to discuss the next steps in the regulatory clinical pathway with regulatory authorities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments